Characterization and cost–benefit analysis of automated bioreactor‐expanded mesenchymal stem cells for clinical applications

Abstract

MSCs manufactured by an automated bioreactor are physically and functionally equivalent to the MSCs manufactured by the manual flask method and have met the standards required for clinical application.